Rigel Pharmaceuticals, Inc. RIGL

Key data

The business

Rigel is a commercial hematology and oncology company that sells pills a specialist prescribes and a patient swallows at home. TAVALISSE (fostamatinib) is a SYK inhibitor for chronic immune thrombocytopenia, an autoimmune disorder that destroys platelets. REZLIDHIA (olutasidenib) is an IDH1 inhibitor for relapsed acute myeloid leukemia; its approval rested on a 153-patient Phase 2 registrational trial reported at ASCO in June 2021 (NCT02719574). GAVRETO (pralsetinib), in-licensed, treats RET-driven lung and thyroid cancers. Revenue is product sales plus lumpier contract and royalty income from partners who sell these drugs abroad. The moat is narrow but real: orphan indications with few competitors, patent exclusivity, and a commercial sales force already calling on these same doctors, which is why bolting on a fourth and fifth product costs little.

The numbers

Q4 2025's $268 million profit is almost entirely a non-cash tax gain: once Rigel turned durably profitable it released the reserve against its old losses, booking a one-time benefit that flatters every trailing multiple.

Strip it and quarterly earnings run $0.44 to $0.88. The trailing 2.9x P/E is an accounting mirage. On the roughly $3 of earnings the business actually makes this year, you are paying high-teens.

The 2021 per-share figure sits on a far larger share count than today's roughly 19 million. The real inflection is 2024: operating income went from minus $20 million in 2023 to plus $24 million in 2024 to plus $125 million in 2025, and cash from operations from minus $6 million to plus $76 million. This is a company that stopped burning and started printing. What the market is anchored on is the illusory 3x and the tax-gain headline; what it is missing is that normalized earnings are modest, so the case does not rest on cheapness. It rests on the base holding and two free options paying off. The print that settles it is second-half revenue: $137.5 million in the first half against a $285 to $295 million guide means the back half must step up about 10%.

Management

CEO Raul Rodriguez runs a tidy book. Over the last twelve months insiders sold $306 thousand across three sales and bought nothing: a director, Walter Moos, sold $145 thousand in February, and a former officer sold the rest; plan status is not disclosed on any of them. These are small, discretionary trims against a $900 million company, not a signal, but the absence of a single open-market buy is the one soft note. Capital allocation is disciplined: long-term debt paid down from $60 million to $45 million, a small $3.7 million buyback in early 2026, and self-funding entirely from operations. Guidance was updated at $285 to $295 million for the year.

How it fails or surprises you

R289 data lands (right tail). The pipeline asset, R289, is a dual IRAK1/4 inhibitor in open-label Phase 1b for lower-risk MDS patients who failed prior therapy, a large underserved group; efficacy is not yet peer-reviewed. Recommended Phase 2 dose is due in the second half of 2026, with data likely at ASH in December. A clean signal opens a market the stock is not pricing.

VEPPANU ramps (right tail). VEPPANU (vepdegestrant), an oral ER degrader launched in mid-August, is excluded from the $255 to $265 million product-sales guide entirely. Any meaningful uptake in ESR1-mutant breast cancer over the next two prints is upside the model treats as zero today.

The base is lumpier than it looks. If product sales flatten while collaboration income fades, the high-teens normalized multiple compresses toward the 2024 level, and the $255 to $265 million target is the number that would reveal it first.

Closing thoughts

The base business is roughly fairly priced: high-teens on normalized earnings, 9.4x EBITDA, a net-cash balance sheet that buffers the downside. So the edge here is not cheapness, and anyone buying on the 3x trailing P/E is buying an accounting artifact. The edge, if there is one, is the two options the market values at nothing: VEPPANU's ramp and R289's readout. A specific print converts them, the recommended Phase 2 dose and ASH data late this year; an ambiguous readout leaves you holding a profitable, self-funding specialty franchise growing off a lumpy base, which is not a disaster but is not the reason to own it either. The skew is modestly positive because profitability and net cash cap the loss while R289 in a large MDS population is genuine optionality.

The bet is still that Rigel keeps selling more of the same three pills to the same doctors and keeps the cash. What breaks it is product sales stalling: watch second-half revenue against the first half's $137.5 million and the $285 to $295 million guide. If the back half does not build toward that number while contract income slides, the base is thinner than it looks and only R289 saves the story.